Pharmaceuticals

FDA approves Biocon Biologics’ Eylea biosimilar Yesafili to treat multiple eye diseases

bexib
By bexib 0 Min Read

Yesafili’s approval marks Biocon’s entry into the US ophthalmology market, following previous approvals in Europe and the UK.

You Might Also Like

APL and CurifyLabs Partner to Support Patients with 3D Printed Medical Technology

Phase 2 PREDICT-ILD Imaging Study in Interstitial Lung Disease Begins

New ways to determine drug value with health equity in mind

Melissa Krebs Shares Gersana’s Vision for Innovative Wound Care Solutions

Zongertinib demonstrates high objective response rates in previously treated advanced non-small cell lung cancer

Share This Article
Previous Article Dismantling The Cash-flow Narrative: Real Estate vs. Bitcoin
Next Article Bean and Corn Prices, Drought Insurance Options, Technology Integration, March 20, 2024 – RealAgriculture
Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Large-scale inference models accelerate content marketing
Retail & E-commerce
Selfridges ringing in the new year on the roof of San Carlo’s Alto
Hospitality & Tourism
Season 2024: Exceeding expectations at Borghese Contemporary Hotel
Hospitality & Tourism
JPMorgan and Bank of America respond to CFPB lawsuit
Banking